Kornimate/medical-research-clean huggingface dataset:
implementation intention for physical activity in multiple sclerosis

Conditions: Motivation; Mindfulness

Summary: the purpose of this study is to evaluate the effectiveness of an 8-week intervention based on implementation intention (motivation) in patients with multiple sclerosis on objectively measured physical activity.


Eligibility criteria:
inclusion criteria: * adult aged between 18 and 65 years * multiple sclerosis * recruited from chu poissy saint germain or hôpital raymond-poincaré * informed consent provided during inclusion interview exclusion criteria: * already participating in a clinical trial * cognitive dysfunctions in understanding simple guidelines * treatment reducing fatigue since less than 3 months * psychiatric disorders * unability to exercise * previous cardiovascular diseases * regular physical activity practice

Keywords: physical activity multiple sclerosis motivation intention mindfulness
motorized continuous cold therapy versus standard post-op icing protocol for two foot and ankle procedures

Conditions: Narcotic Consumption; Pain; Wound Healing; Patient Satisfaction

Summary: this study will compares differences in pain level, narcotic consumption, wound healing, patient satisfaction in patients randomized to the iceman® cold pack therapy system (djortho, inc) versus those who use ice. this will be assessed postoperatively following the foot and ankle procedures primary first metatarsal osteotomy (pmo) or lateral ankle ligament reconstruction (lar).


Eligibility criteria:
inclusion criteria: * patients who are scheduled to have either lateral ankle ligament reconstruction (lar) surgery or primary first metatarsal osteotomy surgery * patients who agree to be compliant and to keep a patient diary daily for 2 weeks and to return to the clinic for a 2 week postoperative follow- up appointment exclusion criteria: * patients with diabetes mellitus, peripheral vascular disease, reynauds syndrome, hypersensitivity to cold * patients allergic to hydrocodone or oxycodone * patients who are unwilling to complete the patient diary and/or follow their specific cold therapy instructions

Keywords: cryotherapy postoperative pain iceman primary first metatarsal osteotomy (pmo) lateral ankle ligament reconstruction (lar)
artificial intelligence-assisted glaucoma screening (aiags)

Conditions: Glaucoma Eye

Summary: this study will develop an artificial intelligence (ai) program for the screening of glaucoma.

we have realized that the glaucomatous optic neuropathy is irreversible. but if early detection and early intervention can be performed to control the development of the disease, it can greatly reduce the blindness rate of glaucoma, improve the life quality and physiological and mental health of patients, and alleviate the social burden. therefore, screening and early diagnosis of glaucoma is the focus of glaucoma prevention. china has a population of 1.3 billion, which greatly increase the difficulty of disease screening. in recent years, the intersection of artificial intelligence (ai) technology and modern medicine has made efficient and rapid disease screening possible.

Eligibility criteria:
inclusion criteria: * able to complete fundus images exclusion criteria: * unable to complete fundus images

Keywords: artificial intelligence; glaucoma
radiofrequency ablation using octopus electrodes for treatment of focal liver malignancies: follow-up study

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to compare the therapeutic outcomes and safety of the study patients who received radiofrequency ablation (rfa) using separable clustered electrodes with those of a matched historical control group who had received rfa using multiple internally-cooled electrodes.

although rfa is widely used as a curative treatment option for a variety of liver malignancies, it is generally limited for treating tumors larger than 2 cm in diameter with a sufficient tumor-free margin. thus, various strategies are employed to create a sufficient ablation zone such as internally cooled-electrodes, expandable electrodes and adaptation of switching mono/bipolar controllers. despite that these attempts have created larger ablative zones in clinical and preclinical studies, the efficacy should be validated in terms of clinical outcome. in this study, investigators evaluated the therapeutic outcomes and safety of rfa using separable clustered electrodes for treatment-naive hepatocellular carcinomas (hccs) in comparison with rfa using multiple internally-cooled electrodes. the study group is a subgroup of our prospective study cohort (nct02683538) and a control group is a matched historical group received rfa in our institution using multiple internally-cooled electrodes.

Eligibility criteria:
inclusion criteria * hcc diagnosed on biopsy or typical imaging features of hcc on ct or mri according to aasld guidelines * 1-3 hccs equal to or smaller than 5cm in the liver * no direct contact with or invasion into the hepatic hilar structures or inferior vena cava * treatment-naive hcc exclusion criteria * patients with uncontrolled coagulopathy * patients with child-pugh classification c * patients with tumor invasion into the portal vein or hepatic vein * extrahepatic spread

Keywords: rfa
lung and cardiac ultrasound for respiratory distress in elderly

Conditions: Dyspnea; Respiratory Distress Syndrome

Summary: prospective trial to evaluate the impact on the initial therapeutic inadequacy of a management strategy for acute dyspnea in the elderly based on the use of lung and cardiac ultrasonography.

acute dyspnea is a frequent and serious reason of admission in emergency department (ed), with a one-month mortality close to 16%. it is difficult to diagnose in the initial assessment phase since the cause of this symptom can vary (cardiological, pulmonary, infectious, etc.) and the symptoms can be misleading. this difficulty in diagnosing delays the implementation of appropriate therapeutic management even as the timeliness of management is associated with a reduction in mortality. these issues are particularly important in the elderly. lung and cardiac ultrasonography performed by the emergency physician, immediately available at the patient's bedside, could reduce the diagnostic and therefore therapeutic delay. however, the impact of a diagnostic strategy based on lung and cardiac ultrasonography in dyspneic elderly subjects has not been evaluated. patients will be randomized in two groups : "standard of care" or "clinical ultrasound" group. treatments initiated in emergency department (ed) will be noted to be compared to final diagnosis.

Eligibility criteria:
inclusion criteria: eligible patients will be aged over 65 years, affiliated with the french social security system, and presenting to the ed with acute dyspnea (onset \<7 days) accompanied by severity signs before or at triage (respiratory rate ≥22 or spo2 \<92% on room air). the enrolling emergency physician (ep) must be the patient's treating physician and must be trained in lucus. written informed consent from the patient or their legal representative is required for inclusion exclusion criteria: dyspnea secondary to thoracic trauma, dyspnea clearly related to covid-19, known pulmonary fibrosis or lung cancer, prior administration of specific treatment for dyspnea before inclusion, immediate need for endotracheal intubation, patients identified as being at end-of-life, and individuals under legal guardianship or deprived of liberty.

Keywords: elderly point-of-care ultrasound respiratory distress syndrom
montelukast in pediatric patients aged 6 to 24 months with asthma--safety study (0476-176)

Conditions: Asthma

Summary: a study of montelukast compared to placebo in asthmatic children aged 6-24 months.


Eligibility criteria:
inclusion criteria: * patient is in good, stable health * patient has been fed solid foods for at least 1 month * patients had at least 3 episodes of asthma or asthma-like symptoms, all occurring after 8 weeks of age; at least one within 6 months of the prestudy visit * patients had to be in need of a controller therapy according to criteria established in the global initiative for asthma (gina) guidelines exclusion criteria: * patient was hospitalized at the start of the study or required a visit to the emergency room due to asthma with in past 2 weeks
safety extension study of tro19622 in als

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of the assay is to assess the safety of tro19622 330 mg qd as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from als, after completion of the preceding clinical trial (tro19622 cl e q 1015-1) in an open label extension.

entry of a patient into this safety study is intended to occur immediately after the patient has finished participating in the preceding efficacy study (protocol tro19622 cl e q 1015-1). the investigator will explain to the patients the nature of this open-label safety study, its procedures, requirements and restrictions so as to obtain their written informed consent. each patient will be treated with olesoxime (tro19622) until the results of the double-blind trial become available with a maximum of 15 months. follow-up visits will take place every 3 months (+/- 2 weeks). safety assessments will be performed at all visits (every 3 months).

Eligibility criteria:
inclusion criteria: * patients must have completed the 18-month safety and efficacy study of tro19622 in amyotrophic lateral sclerosis (als) patients treated with riluzole (protocol tro19622 cl e q 1015-1). * both the investigator and the patient will decide based on previous good tolerance and other clinical grounds whether or not to participate to the open-label extension. * if patients were on anti-vitamin k during the double-blind period, when entering the open-label extension, coagulation tests should be monitored in exactly the same conditions as if a new anticoagulant treatment was initiated and the dose of anti-vitamin k should be adjusted accordingly. * patients enrolling from this prior safety and efficacy study must: * if female of childbearing age of potential, continue to use adequate birth control methods and have a negative serum pregnancy test at the preceding double-blind protocol termination visit. male and female partners must agree to use an effective method of birth control during their participation in the trial and for at least 15 days after the last imp dose. both partners must use reliable methods of contraception with 2 independent methods. the following measures are acceptable: hormone contraceptives (e.g. oral contraceptives or comparable methods), intrauterine device, condoms with spermicidal coating or in combination with spermicidal creams, total abstinence or sterilisation performed in the past. * be able to follow the investigator's instructions and be able to comply with the visit schedule and visit requirements; and * sign a written informed consent. exclusion criteria: patients may not participate in this study if they have an ongoing, unresolved, clinically significant medical problem (including patients having experienced serious adverse events or non-serious, but medically significant adverse events during the preceding safety and efficacy study that was assessed to be related to the study medication by the investigator) that in the judgment of the investigator would make it unsafe for the patient to participate in the trial.

Keywords: amyotrophoc lateral sclerosis tro19622 olesoxime trophos
calcium and vitamin d to optimize bone mass in boys with risperidone-induced hyperprolactinemia

Conditions: Risperidone-induced Hyperprolactinemia

Summary: the purpose of this study is to determine whether calcium and vitamin d supplementation, over a nine-month period, optimizes bone mineralization in boys with risperidone-induced hyperprolactinemia. we hypothesize that, by the end of the stuy, children in the supplementation group will have higher bone mineral density compared to those in the placebo group.


Eligibility criteria:
inclusion criteria: 1. males (age range: 5-17yo; inclusive), in treatment with risperidone for ≥ one year. 2. the participants must have two measurements of prolactin ≥ 18.4 ng/ml, obtained within a week. 3. iq \> 35-40 (≥ moderate intellectual disability). 4. an adult parent/guardian must be available to provide consent and dispense study medication. exclusion criteria: 1. chronic disorders involving a vital organ (heart, lung, liver, kidney, brain), metabolic diseases (e.g., diabetes, hypo- or hyperparathyroidism, hypo- or hyperthyroidism, growth hormone deficiency), other skeletal diseases (e.g., paget's disease, osteogenesis imperfecta, rheumatoid arthritis), chronic use of drugs affecting bone metabolism (e.g., corticosteroids), and malnutrition conditions (e.g., chronic diarrhea, inflammatory bowel disease), congenital disorders, or lead poisoning. 2. participants receiving calcium or multivitamins in the previous three months. 3. a history of renal calculi and fasting random urine calcium/creatinine ratio \> 0.2 or any other medical disorder that contraindicates the use of calcium or vitamin d (e.g., hypercalcemic states, hypercoagulability disorders, vitamin d toxicity, malabsorption syndrome, or hypersensitivity to vitamin d products). 4. laboratory values outside the normal range, except for prolactin, unless the deviations were not clinically significant (e.g. tsh \< 10 μiu/ml (76)). 5. inability to cooperate with the bmd measurements. 6. bilateral wrist or forearm fractures. 7. eating disorders. 8. non-compliance with the prescribed psychiatric treatment as reflected by an undetectable combined risperidone and 9-hydroxy risperidone blood concentration. 9. plans to move out of state within the next 9 months.

Keywords: risperidone hyperprolactinemia children adolescents antipsychotics prevention calcium vitamin d risperidone-induced hyperprolactinemia
daptomycin as adjunctive therapy for staphylococcus aureus bacteremia

Conditions: Methicillin Susceptible Staphylococcus Aureus Septicemia; Bacteremia

Summary: the purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible s. aureus.

when patients have a blood infection with methicillin-susceptible s. aureus, they will all be treated with the usual standard of care, including abeta-lactam antibiotic, have their blood tested daily for the presence of the infection until they test negative, as well as an ultrasound of the heart to rule out an infection of the heart valves, as well as have any catheters removed (if possible) to ensure adequate control of the infection. this study involves adding a second antibiotic, daptomycin, to the treatment regimen of half of the patients enrolled in this study. daptomycin is approved by health canada for treating blood infections due to staphylococcus aureus. it is currently not used in combination with a beta-lactam for these infections because there is insufficient evidence of benefit to justify the cost. the study participants will receive an additional daily iv therapy which will consist of either daptomycin or a placebo for a total of five days while admitted to the hospital. during this time, the participants will continue to have their blood drawn to assess for the presence of bacteria. the participants' liver and muscle enzymes will also be measured on the first and fifth day of therapy to test for potential side effects of the daptomycin.

Eligibility criteria:
inclusion criteria: * patient has a methicillin susceptible staphylococcus aureus bacteremia. exclusion criteria: * underlying terminal illness * significant contraindication to beta-lactam therapy (i.e. severe allergy, severe adverse drug reaction) * expected death before 5 days * microbiologically confirmed need for concomitant vancomycin or daptomycin

Keywords: staphylococcus aureus bacteremia daptomycin
full-mouth periodontal debridement and metronidazole gel in patients with chronic periodontitis

Conditions: Chronic Periodontitis

Summary: hypothesis: metronidazole gel applied topically after periodontal debridement in smokers volunteers could improve clinical parameters when compared to metronidazole tablets + periodontal debridement. method: 30 smokers with chronic periodontitis were randomly assigned into 3 groups: periodontal debridement combined with 3 g placebo gel; periodontal debridement combined with daily topical application of 3 g metronidazole benzoate gel (15%); and periodontal debridement combined with a daily single dose of 750 mg metronidazole. clinical parameters evaluated were visible plaque, gingival bleeding, probing pocket depth and relative attachment level.

background. the benefit of adjunctive metronidazole on periodontal procedure in smokers with chronic periodontitis (cp) is uncertain. the authors compared the effect of metronidazole (mtz) on full-mouth periodontal debridement (pd= 1 hour of ultrasonic calculus/plaque removal) in smokers with cp. methods. this pilot study involved 30 individuals (having at least six teeth with a clinical attachment loss of ≥ 5 mm and probing pocket depth (ppd) of ≥5 mm) that were randomly assigned into three groups (n=10): 1) pd plus 3 g of placebo gel daily topical application 2) pd plus daily topical application of 3 g of 15% mtz benzoate gel; and 3) pd plus a daily single dose of 750 mg mtz (flagyl®). clinical parameters visible plaque index (vpi), gingival bleeding index (gbi), relative attachment level (ral) and ppd; and the quantitative analysis (real-time pcr) of aggregatibacter actinomycetemcomitans, porphyromonas gingivalis and tannerella forsythia were assessed baseline, 1, 3 and 6 months after pd.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic periodontitis * presence of at least 6 periodontal pockets with a clinical attachment loss of ≥5 mm * bleeding on probing (bop) * radiographic bone loss * probing pocket depth higher or equal to 5 mm in at least six teeth * at least 20 teeth in mouth (third molars excluded) * an established smoking habit (at least 10 cigarettes per day for the past 4 years) exclusion criteria: * periapical alterations in qualifying teeth * medical disorders requiring prophylactic antibiotic therapy or interfering with the treatment * periodontal treatment in the past 6 months * use of drugs known to affect periodontal status (antibiotic, anti-inflammatory, anticonvulsant, immunosuppressant and calcium channel blocker) within the past 6 months * orthodontic therapy * pregnancy and lactation * allergy to metronidazole * any systemic diseases (e.g.: diabetes and immunological disorders)

Keywords: chronic periodontitis metronidazole
intervention to promote survivor resilience and adjustment: efficacy evaluation

Conditions: Traumatic Brain Injury

Summary: 1. to evaluate the short and longer-term efficacy of a structured outpatient intervention program (the resilience and adjustment intervention, rai) to improve survivors' resilience. 2. to evaluate the impact of treatment on emotional well-being and postinjury adjustment. 3. to evaluate the impact of the intervention on abilities including problem solving, communication, and stress management. 4. to examine the extent to which treatment benefits are sustained in the longer-term.

to design effective resilience interventions, a treatment modality which is effective for traumatic brain injury (tbi) survivors is needed. virginia commonwealth university (vcu) researchers have had considerable success in the past several decades developing and evaluating interventions for neurobehavioral, cognitive, and vocational challenges after tbi. researchers have demonstrated the utility of the curriculum-based (c-b) treatment structure in various settings. additionally, the efficacy of the c-b structure, independent of postinjury timeframe, allows the flexibility necessary to address the unique consequences of tbi. the c-b treatment modality offers a promising strategy for the promotion of resilience postinjury. the primary purpose of the study is to evaluate the efficacy of a structured, curriculum-based intervention to promote postinjury resilience and adjustment. objectives include: 1. to evaluate the short and longer-term efficacy of a structured outpatient intervention program (the resilience and adjustment intervention, rai) to improve survivors' resilience 2. to evaluate the impact of treatment on emotional well-being and postinjury adjustment 3. to evaluate the impact of the intervention on abilities including problem solving, communication, and stress management 4. to examine the extent to which treatment benefits are sustained in the longer-term

Eligibility criteria:
inclusion criteria: * mild, moderate, or severe tbi * able to understand and provide consent exclusion criteria: * active substance abusers (e.g., intoxicated at arrival to intake) * at imminent risk of psychiatric hospitalization * in imminent danger of hurting themselves or others

Keywords: traumatic brain injury
pilates training in patients with allergic rhinitis

Conditions: Allergic Rhinitis

Summary: the purpose of this study was to determine the effects of pilates training on symptoms in patients with allergic rhinitis.

twenty allergic rhinitis patients aged 18 - 35 years were randomized into 2 groups: control group (con; n=9) and pilates training group (ptg; n=11). participants in con group do their daily routine without receiving any training program, while those in ptg group completed receiving pilates training program three time a week for ten week-long (60 minutes/time). the physiological data, rhinitis symptoms, cytokines, pulmonary function, respiratory muscle strength were analyzed during the pre-test and post-tests. the dependent variables between pre-test and post-tests were analyzed by paired t-test. the rhinitis symptoms and cytokines variables between pre-test and post-test were analyzed by repeated measures anova. in addition, an independent t-test was used to compare the variables between groups. statistical significance was defined as p \< .05.

Eligibility criteria:
inclusion criteria: * the persistent allergic rhinitis who had rhinitis symptoms more than 4 days a week and positive skin prick test to house dust mite were recruited * stopped taking all medicine before the study sus as antihistamine for 3 days, oral steroid and nasal steroid for at least 2 weeks and leukotriene receptor antagonist for at least a week prior to the study * had no exercise program, non-smoking and without any food supplementation for at least 6 months prior to the start of the study exclusion criteria: * had complications with allergic rhinitis, sinusitis, ear tube malfunctions, asthma, lung cancer, emphysema, lower back pain, tendinitis and arthritis

Keywords: allergic rhinitis pilates cytokine pulmonary function rhinitis symptoms
novel photosensitizer in the treatment of chronic periodontitis

Conditions: Periodontitis; Alveolar Bone Loss

Summary: the aim of this study is to evaluate the periodontal outcomes after applying antimicrobial photodynamic therapy with a novel photosensitizer as compared to laser assisted scaling and root planing alone.

laser assisted srp followed by antimicrobial photodynamic therapy with a novel photosensitizer dye phthalocyanine will be done in test group subjects.

Eligibility criteria:
inclusion criteria: * systemically healthy male and female patients of age 30-60 years with generalized probing pocket depths (ppd) indicative of chronic periodontitis and with atleast two sites with ppd ≥5mm in each quadrant exclusion criteria: * medically compromised patients, subjects with a history of periodontal intervention within 6 months of the commencement of the study and smokers